Search Patents
  • Inhibition of histone methyltransferase for cardiac reprogramming
    Patent number: 10130637
    Abstract: A method for promoting the reprogramming of a non-cardiomyocytic cell or tissue into cardiomyocytic cell or tissue comprising is carried out by contacting a non-cardiomyocytic cell or tissue with a modulator of histone methyltransferase activity or expression.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: November 20, 2018
    Assignee: DUKE UNIVERSITY
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Direct Reprogramming of Cells to Cardiac Myocyte Fate
    Publication number: 20140011281
    Abstract: A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.
    Type: Application
    Filed: July 8, 2011
    Publication date: January 9, 2014
    Applicant: DUKE UNIVERSITY
    Inventors: Victor J. Dzau, Maria Mirotsou, Tilanthi Jayawardena
  • Use of HASF as a Protective Agent Against Ischemic Tissue Damage
    Publication number: 20120172306
    Abstract: A method of inducing a protective response against ischemic tissue damage is carried out by administering to subject a composition comprising an HASF polypeptide. The composition is administered prior to an ischemic event such as myocardial infarction to reduce tissue damage associated with such an event.
    Type: Application
    Filed: March 15, 2010
    Publication date: July 5, 2012
    Applicant: Duke University
    Inventors: Maria Mirotsou, Victor J. Dzau, Jing Huang
  • Direct reprogramming of cells to cardiac myocyte fate
    Patent number: 11534464
    Abstract: A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: December 27, 2022
    Assignee: Duke University
    Inventors: Victor J. Dzau, Maria Mirotsou, Tilanthi Jayawardena
  • Direct reprogramming of cells to cardiac myocyte fate
    Patent number: 10695378
    Abstract: A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: June 30, 2020
    Assignee: Duke University
    Inventors: Victor J. Dzau, Maria Mirotsou, Tilanthi Jayawardena
  • Method of reducing cell death by administering a paracrine factor of a mesenchymal stem cell
    Patent number: 8703710
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death and/or tissue injury associated with ischemic conditions.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: April 22, 2014
    Assignees: The Brigham and Women's Hospital, Inc., Duke University
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Direct reprogramming of cells to cardiac myocyte fate
    Patent number: 9987309
    Abstract: A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: June 5, 2018
    Assignee: DUKE UNIVERSITY
    Inventors: Victor J. Dzau, Maria Mirotsou, Tilanthi Jayawardena
  • Method of reducing cell death by administering a paracrine factor derived from a mesenchymal stem cell
    Patent number: 9353168
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death and/or tissue injury associated with ischemic conditions.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: May 31, 2016
    Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DUKE UNIVERSITY
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Method of reducing cell death by administering a nucleic acid encoding a paracrine factor of a mesenchymal stem cell
    Patent number: 9279012
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: March 8, 2016
    Assignees: The Brigham and Women's Hospital, Inc., Duke University
    Inventors: Victor J. Dzau, Maria Mirotsou
  • Method of reducing cell death by administering a Sfrp polypeptide
    Patent number: 8129344
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic condtions.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: March 6, 2012
    Assignees: Duke University, The Brigham and Women's Hospital, Inc.
    Inventors: Victor Dzau, Maria Mirotsou
  • Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
    Publication number: 20060009407
    Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host.
    Type: Application
    Filed: December 22, 2004
    Publication date: January 12, 2006
    Inventors: John Cooke, Victor Dzau, Gary Gibbons
  • Method of enhancing cardiac tissue repair by administering a SFRP polypeptide
    Patent number: 7638128
    Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.
    Type: Grant
    Filed: August 21, 2006
    Date of Patent: December 29, 2009
    Assignees: The Brigham and Women's Hospital, Inc., Duke University
    Inventors: Victor Dzau, Maria Mirotsou
  • Selective inhibition of vascular smooth muscle cell proliferation
    Publication number: 20040266712
    Abstract: The present invention concerns methods and means for selective inhibition of vascular smooth muscle cell (VMSC) proliferation, without negative impact on the proliferation of endothelial cells. In particular, the invention concerns the inhibition of VMSC proliferation without substantial inhibition of endothelial cell proliferation or function by delivery to a blood vessel in need of healing an E2F decoy oligonucleotide.
    Type: Application
    Filed: April 6, 2004
    Publication date: December 30, 2004
    Inventors: Leslie M. McEvoy, Michael J. Mann, Christi Parham, Victor J. Dzau
  • Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
    Publication number: 20020013288
    Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host.
    Type: Application
    Filed: August 15, 2001
    Publication date: January 31, 2002
    Inventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
  • MESENCHYMAL STEM CELLS AND METHODS OF USE THEREOF
    Publication number: 20110091430
    Abstract: The invention provides compositions and methods of enhancing the viability of primary stem cells and enhancing the engraftment of transplanted stem cells into a mammalian recipient. Accordingly, the invention includes a method of regenerating a mesenchymally-derived tissue by contacting the tissue with a composition containing an isolated adult mesenchymal stem cell, which are apoptosis-resistant. The mesenchymal stem cell is an adult cell obtained from an adult bone marrow.
    Type: Application
    Filed: January 19, 2010
    Publication date: April 21, 2011
    Inventors: Victor J. Dzau, Abeel Mangi, James Edmund Ip
  • Mesenchymal stem cells and methods of use thereof
    Publication number: 20040258669
    Abstract: The invention provides compositions and methods of enhancing the viability of primary stem cells and enhancing the engraftment of transplanted stem cells into a mammalian recipient. Accordingly, the invention includes a method of regenerating a mesenchymally-derived tissue by contacting the tissue with a composition containing an isolated adult mesenchymal stem cell, which are apoptosis-resistant. The mesenchymal stem cell is an adult cell obtained from an adult bone marrow.
    Type: Application
    Filed: November 5, 2003
    Publication date: December 23, 2004
    Inventors: Victor J. Dzau, Abeel Mangi, James Edmund Ip
  • Homing of cells to myocardium
    Publication number: 20080070830
    Abstract: The invention provides compositions such modified cells and methods of promoting healing of an injured tissue by enhancing the migration of primary or immortalized progenitor or stem cells and enhancing their engraftment into a target tissue site in mammalian recipient such as a human subject. For example, the cells are adult bone marrow derived cells, such as mesenchymal stem cells (MSC) or hematopoetic stem cells such a endothelial progenitor cells (EPCs) and the target tissue is an injured and/or ischemic heart.
    Type: Application
    Filed: July 26, 2007
    Publication date: March 20, 2008
    Inventors: Victor Dzau, Yaojiong Wu
  • Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
    Publication number: 20020091160
    Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host. Alternatively, or in combination, other compounds may be administered which provide for short term enhancement of nitric oxide, either directly or by physiological processes.
    Type: Application
    Filed: February 1, 2002
    Publication date: July 11, 2002
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
  • Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
    Publication number: 20040082659
    Abstract: Vascular function and structure is maintained or improved by long term administration of physiologically acceptable compounds which enhance the level of endogenous nitric oxide or other intermediates in the NO induced relaxation pathway in the host.
    Type: Application
    Filed: July 15, 2003
    Publication date: April 29, 2004
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John P. Cooke, Victor J. Dzau, Gary H. Gibbons
  • VEGF gene transfer into endothelial cells for vascular prosthesis
    Patent number: 5785965
    Abstract: Endothelial cells derived from subcutaneous adipose tissue are genetically modified to express the endothelial cell-specific angiogenic factor VEGF. The modified cells are sodded onto a vascular prosthesis for transplantation into an autologous or allogeneic recipient. The method accelerates endothelialization on the luminal surface of the vessel, and promotes collateral circulation in distal ischemic organs.
    Type: Grant
    Filed: May 15, 1996
    Date of Patent: July 28, 1998
    Assignee: The Board of Trustees of the Leland Stanford Junior Univ.
    Inventors: Richard E. Pratt, Victor J. Dzau
Narrow Results

Filter by US Classification